サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1768522

ガンマナイフの世界市場

Gamma Knife

出版日
ページ情報
英文 189 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
ガンマナイフの世界市場
出版日: 2025年07月11日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 189 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ガンマナイフの世界市場は2030年までに4億390万米ドルに達する見込み

2024年に3億1,080万米ドルと推定されるガンマナイフの世界市場は、分析期間2024～2030年にCAGR 4.5％で成長し、2030年には4億390万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである悪性腫瘍は、CAGR 4.7%を記録し、分析期間終了時には2億2,110万米ドルに達すると予測されます。良性腫瘍セグメントの成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は8,220万米ドルと推定、中国はCAGR6.9％で成長予測

米国のガンマナイフ市場は、2024年に8,220万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8,730万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9％と3.7％と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界のガンマナイフ市場- 定義、主要動向と促進要因まとめ

ガンマナイフとは何か、なぜ現代の脳神経外科で重要なのか？

ガンマナイフは定位放射線手術（SRS）の一種で、侵襲的な手術を行わずに脳腫瘍、血管奇形、その他の神経疾患を治療するために使用されます。しかし、なぜガンマナイフが脳神経外科における画期的な治療法と考えられているのでしょうか？従来の手術とは異なり、ガンマナイフはガンマ線の集束ビームを使って脳の異常組織を正確に狙い、周囲の健康な組織を傷つけることなく高線量の放射線を照射します。この非侵襲的な手術は、その正確性、有効性、回復時間の短縮で知られており、脳転移、動静脈奇形（AVM）、三叉神経痛、ある種の良性・悪性脳腫瘍などの患者さんに好まれています。ガンマナイフは物理的な切開を必要としないため、感染、出血、長期の回復といった従来の脳手術に伴うリスクを最小限に抑えることができます。より低侵襲な治療への需要が高まる中、ガンマナイフテクノロジーは、複雑な脳疾患を正確かつ最小限の副作用で治療できるという点で、現代の脳神経外科においてますます重要性を増しています。

技術進歩はガンマナイフ市場をどのように形成しているか？

技術革新はガンマナイフシステムの進歩に重要な役割を果たしています。しかし、これらの進歩は、どのように手技の有効性と安全性を向上させているのだろうか。1つの大きな開発は、MRIやCTスキャンなどの高度な画像技術をガンマナイフシステムと統合し、治療計画と精度を向上させたことです。これらの画像技術により、脳病変の位置をより正確に特定することができ、放射線を必要な場所に正確に照射し、健康な組織へのダメージを最小限に抑えることができます。また、リアルタイム画像処理と3D治療計画ソフトウェアの導入により、線量照射の精度が向上し、脳転移やAVMなどの疾患に対して、よりターゲットを絞った治療が可能になりました。

もう一つの重要な技術革新は、ガンマナイフ技術自体の進化です。ガンマナイフIconのようなガンマナイフシステムの最新バージョンは、高度なモーショントラッキングと固定システムを搭載しており、フレームレス治療が可能です。これにより、患者の不快感が軽減され、治療可能な病態の幅が広がります。さらに、新しいシステムは分割治療が可能で、必要に応じて複数回に分けて放射線を照射できるため、より大きな病変や複雑な病変の治療にも柔軟に対応できます。

このような技術の進歩により、ガンマナイフ治療はより安全で、より快適で、より効果的なものとなり、医療提供者はより幅広い神経疾患に対する放射線手術の使用を拡大するのに役立っています。

規制とヘルスケア動向はガンマナイフ市場にどのような影響を与えているか？

ガンマナイフ市場の形成において、規制の枠組みやヘルスケア動向はどのような役割を果たしているのでしょうか。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、ガンマナイフ技術の安全性と有効性を確保する上で重要な役割を果たしています。厳格な規制基準がガンマナイフシステムのような医療機器の承認と使用を導き、これらの治療が安全要件を満たし、一貫した高品質の治療を提供することを保証しています。さらに、ヘルスケアプロバイダーは放射線安全基準を遵守しなければなりませんが、これは定位放射線手術の使用が世界的に拡大するにつれて、ますます重要になってきています。

バリュー・ベースのヘルスケアへの動向の高まりも、ガンマナイフ技術の採用に影響を与えています。ヘルスケアシステムがアウトカムベースのモデルへとシフトする中、ガンマナイフのような高精度、副作用の軽減、回復時間の短縮を実現する治療は、患者と医療提供者の双方にとってより魅力的なものとなっています。入院期間やリハビリ期間が長くなる従来の開腹手術に比べ、非侵襲的手術の費用対効果は高く、ガンマナイフ技術への投資を促す病院やクリニックが増えています。さらに、低侵襲治療に対する需要の高まりが、定位放射線手術センターの世界の拡大を後押ししており、特にアジア太平洋やラテンアメリカなどの地域で成長しています。

さらに、世界のがん罹患率の上昇、特に脳転移の増加により、ガンマナイフのような先進的な放射線外科ツールに対するニーズが高まることが予想されます。このような規制やヘルスケアの動向は、ガンマナイフが複雑な脳疾患を治療するための安全で効果的かつ経済的に実行可能な選択肢であり続けることを保証し、市場を形成しています。

ガンマナイフ市場成長の主な促進要因は？

ガンマナイフ市場の成長は、脳疾患の罹患率の増加、放射線外科技術の進歩、低侵襲治療オプションに対する需要の高まりなど、いくつかの重要な要因によってもたらされます。主な促進要因の1つは、脳腫瘍、血管奇形、神経障害の有病率の上昇であり、これにより精密で効果的な治療法に対するニーズが高まっています。ガンマナイフ放射線手術は、最小限のリスクでこれらの疾患を治療できることで広く認知されており、従来の手術の適応とならない患者にとって好ましい選択肢となっています。ガンマナイフ治療の精度と安全性を向上させた画像技術と放射線技術の進歩も大きな推進力となっています。これらの技術革新により、ヘルスケアプロバイダーはより複雑な症例の治療、患者の転帰の改善、副作用の軽減が可能になりました。さらに、高齢化社会はガンマナイフ市場の成長に寄与しています。高齢の患者は脳疾患のリスクが高いことが多く、非侵襲的な治療を求める傾向が強いからです。

また、患者やヘルスケアプロバイダーは、回復が早く合併症の少ない治療を求めているため、外来治療の需要も高まっています。ガンマナイフの治療は通常、一晩の入院が不要であるため、外来患者にとって魅力的な選択肢となっています。ガンマナイフセンターが世界的に、特に新興市場で利用可能になりつつあることは、より多くのヘルスケアプロバイダーがこの最先端技術に投資することで、市場拡大をさらに後押ししています。非侵襲的治療に対する需要の高まり、技術の進歩、神経疾患の負担増といった要因が相まって、ガンマナイフの世界市場は力強い成長を遂げており、脳神経外科の将来における重要なツールと位置づけられています。

セグメント

適応症（悪性腫瘍、良性腫瘍、血管障害、機能障害、眼疾患）

調査対象企業の例

  • Accuray, Inc.
  • Brainlab AG
  • Elekta AB
  • Elsan SAS
  • IBA Dosimetry GmbH
  • Mevion Medical Systems, Inc.
  • Panacea Medical Technologies Pvt. Ltd.
  • Sun Nuclear Corporation
  • Varian Medical Systems, Inc.
  • Zap Surgical Systems Inc.

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP21871

Global Gamma Knife Market to Reach US$403.9 Million by 2030

The global market for Gamma Knife estimated at US$310.8 Million in the year 2024, is expected to reach US$403.9 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Malignant Tumors, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$221.1 Million by the end of the analysis period. Growth in the Benign Tumors segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$82.2 Million While China is Forecast to Grow at 6.9% CAGR

The Gamma Knife market in the U.S. is estimated at US$82.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$87.3 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Gamma Knife Market - Definition, Key Trends & Drivers Summarized

What Is Gamma Knife and Why Is It Important in Modern Neurosurgery?

Gamma Knife is a form of stereotactic radiosurgery (SRS) used to treat brain tumors, vascular malformations, and other neurological conditions without invasive surgery. But why is Gamma Knife considered a breakthrough in neurosurgery? Unlike traditional surgery, Gamma Knife uses focused beams of gamma radiation to precisely target abnormal tissue in the brain, delivering high doses of radiation without harming surrounding healthy tissue. This non-invasive procedure is known for its accuracy, effectiveness, and reduced recovery time, making it a preferred option for patients with conditions like brain metastases, arteriovenous malformations (AVMs), trigeminal neuralgia, and certain types of benign and malignant brain tumors. Since Gamma Knife does not require physical incisions, the risks associated with traditional brain surgery-such as infection, bleeding, and extended recovery-are minimized. As demand for less invasive treatments grows, Gamma Knife technology has become increasingly important in modern neurosurgery for its ability to treat complex brain conditions with precision and minimal side effects.

How Are Technological Advancements Shaping the Gamma Knife Market?

Technological innovations are playing a key role in advancing Gamma Knife systems. But how are these advancements improving the effectiveness and safety of the procedure? One major development is the integration of advanced imaging technologies, such as MRI and CT scans, with Gamma Knife systems to enhance treatment planning and accuracy. These imaging techniques allow for more precise localization of brain lesions, ensuring that radiation is delivered exactly where it is needed, minimizing damage to healthy tissue. The incorporation of real-time imaging and 3D treatment planning software has also improved the precision of dose delivery, enabling more targeted treatments for conditions like brain metastases and AVMs.

Another key innovation is the evolution of the Gamma Knife technology itself. The latest versions of Gamma Knife systems, such as the Gamma Knife Icon, feature advanced motion tracking and immobilization systems, allowing for frameless treatments. This reduces patient discomfort and expands the range of treatable conditions. Moreover, new systems offer the ability to deliver fractionated treatments, meaning that radiation can be delivered over multiple sessions if needed, providing more flexibility for treating larger or more complex lesions.

These technological advancements are making Gamma Knife treatments safer, more comfortable, and more effective, helping healthcare providers expand the use of radiosurgery for a broader range of neurological conditions.

How Are Regulations and Healthcare Trends Impacting the Gamma Knife Market?

What role do regulatory frameworks and healthcare trends play in shaping the Gamma Knife market? Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a critical role in ensuring the safety and efficacy of Gamma Knife technology. Strict regulatory standards guide the approval and use of medical devices like Gamma Knife systems, ensuring that these treatments meet safety requirements and deliver consistent, high-quality care. Additionally, healthcare providers must comply with radiation safety standards, which are becoming increasingly important as the use of stereotactic radiosurgery expands globally.

The growing trend toward value-based healthcare is also influencing the adoption of Gamma Knife technology. As healthcare systems shift toward outcomes-based models, treatments that offer high precision, reduced side effects, and shorter recovery times-such as Gamma Knife-are becoming more attractive to both patients and providers. The cost-effectiveness of non-invasive procedures, compared to traditional open surgery with longer hospitalization and rehabilitation periods, is encouraging more hospitals and clinics to invest in Gamma Knife technology. Moreover, the rising demand for minimally invasive treatments is driving the expansion of stereotactic radiosurgery centers globally, with particular growth in regions such as Asia-Pacific and Latin America.

Furthermore, as the global burden of cancer continues to rise, particularly with the increasing incidence of brain metastases, the need for advanced radiosurgical tools like Gamma Knife is expected to grow. These regulatory and healthcare trends are shaping the market by ensuring that Gamma Knife remains a safe, effective, and financially viable option for treating complex brain conditions.

What Are the Key Drivers Behind the Growth of the Gamma Knife Market?

The growth in the Gamma Knife market is driven by several key factors, including the increasing incidence of brain disorders, advancements in radiosurgical technology, and the growing demand for minimally invasive treatment options. One of the primary drivers is the rising prevalence of brain tumors, vascular malformations, and neurological disorders, which has increased the need for precise and effective treatment modalities. Gamma Knife radiosurgery is widely recognized for its ability to treat these conditions with minimal risk, making it a preferred choice for patients who are not candidates for traditional surgery. Another significant driver is the advancement in imaging and radiation technologies, which have enhanced the accuracy and safety of Gamma Knife treatments. These innovations allow healthcare providers to treat more complex cases, improve patient outcomes, and reduce side effects. Additionally, the aging global population is contributing to the growth of the Gamma Knife market, as elderly patients are often at higher risk for brain conditions and are more likely to seek non-invasive treatments.

The demand for outpatient procedures is also rising, as patients and healthcare providers seek treatments that offer faster recovery times and fewer complications. Gamma Knife treatments typically require no overnight hospital stay, making them an appealing option in outpatient settings. The growing availability of Gamma Knife centers worldwide, particularly in emerging markets, is further driving the expansion of the market as more healthcare providers invest in this cutting-edge technology. Together, these factors-rising demand for non-invasive treatments, technological advancements, and the increasing burden of neurological diseases-are driving robust growth in the global Gamma Knife market, positioning it as a key tool in the future of neurosurgery.

SCOPE OF STUDY:

The report analyzes the Gamma Knife market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders, Ocular Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Accuray, Inc.
  • Brainlab AG
  • Elekta AB
  • Elsan SAS
  • IBA Dosimetry GmbH
  • Mevion Medical Systems, Inc.
  • Panacea Medical Technologies Pvt. Ltd.
  • Sun Nuclear Corporation
  • Varian Medical Systems, Inc.
  • Zap Surgical Systems Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Gamma Knife - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Brain Tumors and Neurological Disorders Drives Demand for Gamma Knife Radiosurgery
    • Technological Advancements in Gamma Knife Systems Propel Growth in Precision Treatment for Complex Brain Conditions
    • Increasing Adoption of Non-Invasive Treatment Solutions Expands Market for Gamma Knife as a Preferred Alternative to Traditional Surgery
    • Growing Focus on Minimally Invasive Neurosurgery Fuels Demand for Gamma Knife in the Treatment of Brain Metastases and Arteriovenous Malformations (AVMs)
    • Rising Demand for Outpatient Treatment Options Strengthens the Business Case for Gamma Knife Radiosurgery Due to Shorter Recovery Times
    • Increasing Use of Gamma Knife for Treating Functional Disorders, Such as Trigeminal Neuralgia, Expands Clinical Applications
    • Technological Innovations in Imaging and Targeting Techniques Propel Growth in Real-Time Monitoring and Enhanced Treatment Accuracy
    • Rising Global Awareness of Stereotactic Radiosurgery (SRS) Strengthens Market Demand for Gamma Knife in Neurological and Oncological Treatments
    • Growing Emphasis on Reducing Side Effects and Enhancing Patient Outcomes Fuels Adoption of Gamma Knife for High-Precision Radiosurgery
    • Increasing Focus on Elderly Patients and Their Unique Treatment Needs Expands Market for Gamma Knife as a Safe and Effective Option
    • Technological Advancements in Motion Tracking and Immobilization Systems Support Growth in Frameless Gamma Knife Treatments
    • Rising Adoption of Gamma Knife in Pediatric Neurosurgery Expands Market for Non-Invasive Treatment of Pediatric Brain Disorders
    • Growing Focus on Value-Based Healthcare Drives Adoption of Gamma Knife as a Cost-Effective Alternative to Open Surgery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Gamma Knife by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Malignant Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Malignant Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Malignant Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Benign Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Benign Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Benign Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Vascular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Vascular Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Vascular Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Functional Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Functional Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Functional Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Ocular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Ocular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Ocular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Gamma Knife Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • JAPAN
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Japan 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • CHINA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: China 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • EUROPE
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Gamma Knife by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Europe 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Europe 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • FRANCE
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: France 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • GERMANY
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Germany 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Italy 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: UK 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Spain 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Russia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Rest of Europe 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Gamma Knife by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Asia-Pacific 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Australia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • INDIA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: India 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: South Korea 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Gamma Knife by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Latin America 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Latin America 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Argentina 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Brazil 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Mexico 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Latin America 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Gamma Knife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Gamma Knife by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Middle East 15-Year Perspective for Gamma Knife by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Middle East 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Iran 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Israel 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Saudi Arabia 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UAE 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Middle East 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030
  • AFRICA
    • Gamma Knife Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Gamma Knife by Indication - Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Africa 15-Year Perspective for Gamma Knife by Indication - Percentage Breakdown of Value Sales for Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders and Ocular Diseases for the Years 2015, 2025 & 2030

IV. COMPETITION